Alphabet, Tencent and Gilead Sciences are in line to achieve exits, after the vaccine developer filed to go public on the Nasdaq Global Market.

Vaccitech, a UK-based cancer and infectious disease vaccine developer backed by corporate investors Alphabet, Tencent and Gilead Sciences, filed for an initial public offering in the US on Friday.

Financial terms have not yet been set and Vaccitech has used a placeholder $100m target in its draft prospectus. It is looking to list on the Nasdaq Global Market and is seeking a valuation of about $700m, according to the Wall Street Journal.

Founded in 2016, Vaccitech originally focused on…